Literature DB >> 23250663

Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus.

Samar Singh1, Jyoti Bhat, Ping H Wang.   

Abstract

Over the past several years, there have been a significant number of new agents developed for the treatment of type 2 diabetes. Our goal in this article is to review the cardiovascular effects (risks and benefits) of these oral and non-insulin injectable agents. We review six major categories of diabetic therapies: biguanides, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, GLP-1 agonists, and DPP-IV inhibitors. In order to achieve a personalized regimen that aims for optimal outcomes, we must take into consideration each drug's side effects, patients' cardiovascular risk factors, and their individual health profile.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23250663     DOI： 10.1007/s11886-012-0327-1

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  61 in total

1.  Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.

Authors:  Floris A van de Laar; Peter L Lucassen; Reinier P Akkermans; Eloy H van de Lisdonk; Guy E Rutten; Chris van Weel
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

2.  A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.

Authors:  Azim S Gangji; Tali Cukierman; Hertzel C Gerstein; Charles H Goldsmith; Catherine M Clase
Journal:  Diabetes Care       Date:  2007-02       Impact factor: 19.112

Review 3.  Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes.

Authors:  Bianca Hemmingsen; Søren S Lund; Jørn Wetterslev; Allan Vaag
Journal:  Eur J Endocrinol       Date:  2009-04-15       Impact factor: 6.664

4.  The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.

Authors:  Shi-Dou Lin; Jun-Sing Wang; Shang-Ren Hsu; Wayne H-H Sheu; Shih-Te Tu; I-Te Lee; Shih-Li Su; Shih-Yi Lin; Shu-Yi Wang; Ming-Chia Hsieh
Journal:  J Diabetes Complications       Date:  2011-08-02       Impact factor: 2.852

Review 5.  Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.

Authors:  P J Palumbo
Journal:  J Diabetes Complications       Date:  1998 Mar-Apr       Impact factor: 2.852

Review 6.  Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies.

Authors:  Daniel Addison; David Aguilar
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

7.  Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.

Authors:  Marianne Zeller; Nicolas Danchin; Dominique Simon; Alec Vahanian; Luc Lorgis; Yves Cottin; Jacques Berland; Pascal Gueret; Pascal Wyart; Régis Deturck; Xavier Tabone; Jacques Machecourt; Florence Leclercq; Elodie Drouet; Geneviève Mulak; Vincent Bataille; Jean-Pierre Cambou; Jean Ferrieres; Tabassome Simon
Journal:  J Clin Endocrinol Metab       Date:  2010-08-11       Impact factor: 5.958

Review 8.  The cardioprotective effects of metformin.

Authors:  Saloua El Messaoudi; Gerard A Rongen; Rudolf A de Boer; Niels P Riksen
Journal:  Curr Opin Lipidol       Date:  2011-12       Impact factor: 4.776

9.  Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.

Authors:  Hiroki Yokoyama; Sakiko Kannno; Ikue Ishimura; Koichi Node
Journal:  Metabolism       Date:  2007-11       Impact factor: 8.694

Review 10.  Incretin-based therapies in type 2 diabetes mellitus.

Authors:  Chee W Chia; Josephine M Egan
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958
View more
  4 in total

Review 1.  Cardiovascular impact of drugs used in the treatment of diabetes.

Authors:  Chris R Triggle; Hong Ding
Journal:  Ther Adv Chronic Dis       Date:  2014-11       Impact factor: 5.091

Review 2.  Cardiovascular safety profile of currently available diabetic drugs.

Authors:  Komola Azimova; Zinnia San Juan; Debabrata Mukherjee
Journal:  Ochsner J       Date:  2014

Review 3.  Coronary artery disease and diabetes mellitus.

Authors:  Doron Aronson; Elazer R Edelman
Journal:  Cardiol Clin       Date:  2014-06-10       Impact factor: 2.213

4.  Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.

Authors:  Peter Bramlage; Anselm K Gitt; Steffen Schneider; Evelin Deeg; Diethelm Tschöpe
Journal:  BMC Cardiovasc Disord       Date:  2014-11-19       Impact factor: 2.298
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.